Supreme Court Economic Showdown: Monsanto, Verizon, and Cisco Face Final 2026 Arguments

WASHINGTON — A wave of corporate giants, including Monsanto, Cisco Systems, and Verizon, are lining up at the U.S. Supreme Court as the justices hear the final arguments of the Spring 2026 term. The court’s conservative majority is being pressed to shield industries from multimillion-dollar jury verdicts, limit the marketing of generic drugs, and neuter the federal government’s ability to issue administrative fines—decisions that could have widespread implications for products ranging from pacemakers to pet food.

‎

Among the most significant cases is an appeal from Monsanto, the agricultural giant owned by Bayer, which is fighting to dismiss thousands of lawsuits from individuals who claim the pesticide Roundup caused their cancer. Oral arguments in Monsanto Company v. Durnell are scheduled for Monday, April 27, 2026. The company is appealing a $1.25 million verdict awarded to a Missouri man, arguing that federal labeling laws (FIFRA) should preempt state-level "failure to warn" claims. Legal experts warn that a win for Monsanto could effectively close courthouse doors for consumers injured by dangerous products across multiple industries.

‎

The telecommunications industry is also seeking relief from the high court. On Tuesday, April 21, the justices heard arguments from Verizon and AT&T challenging more than $100 million in combined fines issued by the Federal Communications Commission (FCC) over the mishandling of customer location data. While the companies argue the fines violate their Seventh Amendment right to a jury trial, Chief Justice John Roberts and members of the liberal bloc appeared receptive to the FCC's position, suggesting that the companies are not legally obligated to pay until a jury trial is eventually granted in a collection suit.

‎

The court is also set to address corporate accountability for international human rights. On April 28, the justices will hear Cisco Systems v. Doe, a case involving allegations that the tech company helped build a surveillance network used by the Chinese government to persecute dissidents. The ruling will determine if U.S. corporations can be held liable under the Alien Tort Statute and the Torture Victim Protection Act for "aiding and abetting" abuses overseas. A decision against the plaintiffs could mark the effective end of such human rights litigation in American courts.

‎

In the pharmaceutical sector, the term will likely conclude with a battle over "skinny labeling" in Hikma v. Amarin. The dispute centers on whether Hikma Pharmaceuticals induced patent infringement for the heart medication Vascepa through its marketing and press releases. Advocates for public health, such as Public Citizen, warn that a ruling against generic manufacturers could deter the sale of lower-cost drugs, significantly increasing healthcare costs for everyday Americans.

‎

While the court under Chief Justice John Roberts has historically backed the U.S. Chamber of Commerce in nearly 70% of cases, recent rulings have been mixed. In February, the court tossed out sweeping emergency tariffs, but more recently, on April 22, the justices sided against corporations in a Michigan pipeline dispute and a lawsuit involving a military contractor and a Bagram Airfield suicide bombing. With final decisions expected by early July, the outcome of these remaining cases will define the boundaries of corporate power and government oversight for years to come.

‎

Explore: NBCPalmSprings.com, where we are connecting the Valley.